Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and...

Descripción completa

Detalles Bibliográficos
Autores principales: Shubrook, Jay, Colucci, Randall, Guo, Aili, Schwartz, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411543/
https://www.ncbi.nlm.nih.gov/pubmed/22879789
http://dx.doi.org/10.4137/CMED.S5114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411543/
https://www.ncbi.nlm.nih.gov/pubmed/22879789
http://dx.doi.org/10.4137/CMED.S5114

Ejemplares similares